NCT06277388Active, not recruiting
Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment.
Hemodynamic Changes and Prognostic Analysis of Patients With Locally Advanced Non-small Cell Lung Cancer During Combined Chemoradiotherapy and Immunotherapy: An Observational Study Based on Dynamic Cardiac Output.
Source: ClinicalTrials.gov · Last updated 11 Mar 2026
Brief summary (registry, in English)
This study aimed to investigate the role of impedance cardiography (ICG) in evaluating hemodynamic changes during the 6-minute walk test (6MWT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who underwent combined concurrent chemoradiotherapy (CCRT) and immunotherapy. Additionally, It sought to analyze the predictive significance of cardiac parameters to both treatment toxicity and survival prognosis.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 231 (actual)
- First submitted
- 18 Feb 2024
- Start date
- Jun 2021
- Primary completion date
- Sept 2025
- Lead sponsor
- Sun Yat-sen University
- Diseases
- Lung cancer
- NCT number
- NCT06277388
What you commit to
- Study type: Observational
- Participants enrolled: 231
- From Jun 2021 to the primary completion date, Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- history of another primary malignancy
- poorly controlled intercurrent illness
- patients with contraindications to 6MWT, including unstable angina pectoris or myocardial infarction within the past month, systolic blood pressure (SBP) over 180mmHg, diastolic blood pressure (DBP) over 100mmHg, muscle strength below grade 3, and severe spasm.
Other
- mixed small cell and NSCLC histology
- life expectancy lower than 12 weeks
- female in pregnancy or breast-feeding and any situation not suitable for this study judged by researchers
Who the study is looking for
- had untreated histologically or cytologically confirmed NSCLC
- be between the age of 18 and 75
- had unresectable stage IIIA-IIIC disease, as defined by the AJCC 8th edition staging system
- had an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0\~1
- had adequate bone marrow function (neutrophil count ≥1.5x109/L, hemoglobin concentration ≥90 g/L, platelet ≥100x109/L), kidney function (serum creatinine clearance ≥50 ml/min) and liver function (serum bilirubin ≤1.5 times upper limit of normal (ULN), aspartate transaminase (AST) and alanine transferase (ALT) ≤2.5 ULN)
- had a forced expiratory volume in 1 second (FEV1) of ≥0.8L.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hui Liu Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.